메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

논문 기본 정보

자료유형
학술저널
저자정보
저널정보
대한간학회 Clinical and Molecular Hepatology Clinical and Molecular Hepatology 제20권 제3호
발행연도
2014.1
수록면
274 - 282 (9page)

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
Background/Aims: Quantitation of hepatitis B surface antigen (HBsAg) is an increasingly popular method to determinethe treatment response in chronic hepatitis B (CHB) patients. The clinical value of HBsAg level measurement duringrescue therapy for lamivudine (LMV)-resistant CHB patients have not been evaluated to date. Therefore, this studyinvestigated the correlation between HBsAg level and treatment response in LMV- resistant CHB patients treated withadefovir (ADV) add-on therapy. Methods: LMV-resistant CHB patients treated with LMV-ADV combination therapy for over 2 years were included. HBsAglevels were measured at 6 month intervals until 1 year, and annually thereafter. Treatment response was assessed bydetermining the virological response (VR, undetectable HBV DNA levels) during treatment. Results: Fifty patients were included, of which 40 showed a VR. HBsAg levels were not different significantly at baseline(4.0 vs. 3.6 Log10 IU/mL, P=0.072). However, the HBsAg level decreased after 6 months of treatment in patients with a VRand became different significantly between the groups thereafter (3.9 vs. 3.3 at 6 months, P=0.002; 3.8 vs. 3.2 at 1 year,P=0.004; 3.9 vs. 3.2 at 2 years, P=0.008; 3.7 vs. 3.1 at 3 years, P =0.020). Conclusions: The HBsAg level at 6 months after treatment can help predict treatment response.

목차

등록된 정보가 없습니다.

참고문헌 (22)

참고문헌 신청

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0